In addition to traditional surgical treatment and chemotherapy, targeted therapies represented by EGFR inhibitors, ALK inhibitors, ROS1 inhibitors and immunotherapies represented by PD‐1/PD‐L1 inhibitors and CTLA‐4 inhibitors are playing an increasingly critical role in the treatment of lung cancer [3, 4, 5]. The gene discussed is ALK; the disease is lung carcinoma.